Akèy › Kansè Endomèt › Texas › Fort Worth
Etid klinik pou Kansè Endomèt nan Fort Worth, TX
12 etid pou Kansè Endomèt ap chèche patisipan nan sit nan ak bò kote Fort Worth (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
Ap rekriteFaz 1
- START Center for Clinical Research, Fort Worth
Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
Ap rekriteFaz 2
- UT Southwestern/Simmons Cancer Center-Fort Worth, Fort Worth
EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors
Ap rekriteFaz 1/2
- START Dallas Fort Worth, Fort Worth
A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
Ap rekriteFaz 3
- Texas Oncology - DFW ( Site 8004), Fort Worth
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
Ap rekriteFaz 1
- Start - Dfw, Fort Worth
Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer
Ap rekriteFaz 3
- USOR - Texas Oncology - Dallas Fort Worth (DFW), Fort Worth
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
Ap rekriteFaz 3
- Research Site, Fort Worth
A Study of PHST001 in Advanced Solid Tumors
Ap rekriteFaz 1
- START Center for Cancer Research - Texas, Fort Worth
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Ap rekriteFaz 1/2
- USOR Texas Oncology, Fort Worth
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
Ap rekriteFaz 1
- UT Southwestern - Simmons Cancer Center - Fort Worth, Fort Worth
A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types
Ap rekriteFaz 1
- START Dallas Fort Worth, LLC, Fort Worth
Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer
Ap rekriteFaz 2/3
- Texas Oncology-Fort Worth Cancer Center, Fort Worth
Etid Kansè Endomèt nan lòt vil
- Houston, TX68 etid
- New York City, NY52 etid
- Boston, MA50 etid
- Arlington, VA39 etid
- Nashville, TN38 etid
- Los Angeles, CA34 etid
- St. Louis, MO29 etid
- Philadelphia, PA28 etid
- San Antonio, TX27 etid
- Chicago, IL25 etid
- Columbus, OH25 etid
- Queens, NY25 etid
Lòt etid nan Fort Worth
- Kansè Poumon ki pa ti selil18 etid
- Kansè ovè17 etid
- Kansè nan tete11 etid
- Kansè (tout kalite)9 etid
- Kansè pwostat9 etid
- Ensifizyans kadyak7 etid
- Kansè kolorektal7 etid
- Kansè tete negatif triple7 etid
- Kansè Metastatik7 etid
- Kansè renn (Kasinom selil renn)7 etid
- Kolit Ulseratif7 etid
- Degeneresans makile7 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.